Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. I knew this through friends, and he was not great but he made the time pass. If taken internally The Cannabis oils will work Systemically to kill the cancers from the inside out. At this time, I would like to turn the conference over to Ms. When outcomes in this study were analyzed based on the extent of monocyte PD-L1 expression, the 50% of patients with less elevated PD-L1 showed markedly better PFS and mOS than historical SOC: PFS of 27 months versus 5-9 months and mOS of 45 months versus 15-19 months. Herpes, a chronic viral infection, impacts some 50 million Americans in the U.S. “If approved, this candidate vaccine may offer an important option for the prevention of shingles, a painful disease that negatively impacts peoples’ health and quality of life,” said Alain Brecx, vaccine development leader at GSK.

Also for royalty-bearing products, Agenus will be eligible to receive tiered royalties on global net sales ranging from mid-single to low-double digit rates, and has reserved the right to elect to co-fund 30% of development costs for increased royalties. Agenus within its HSP Platform is developing its recombinant series and prophage series vaccines. Pfizer EarningsPfizer reported that FX exchange rates negatively impacted revenue by $453 million, but only had a $351 positive impact on costs. QS-21 Stimulon has been widely studied and approximately 50,000 patients have received vaccines containing the adjuvant. Following the third dose, participants were inoculated intra-nasally with pneumococcus serotype 6B. The Retrocyte DisplayTM platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

Agenus’ heat shock protein-based vaccines for cancer and infectious diseases have recently completed Phase 2 studies in newly diagnosed glioblastoma multiforme, and herpes simplex virus type 2 genital herpes. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. You can expect radiation therapy and chemotherapy because they are both shown to increase the chances of surviving cancer. Robert Stein, Chief Scientific Officer. Agenus’ internal and partnered checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed programs. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen Sciences Ireland UC and includes several vaccine candidates in Phase 2, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

Except for the historical information set forth herein, the matters set forth in this press release, including without limitation statements with respect to the initial focus of the alliance, the potential benefits of the alliance and the expectation that the first clinical trials under the alliance will be initiated in 2016, contain predictions and estimates and are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including the high degree of risk associated with drug development, results of further research and development, unanticipated delays, other market or economic factors and technological advances, regulatory approval of the transaction and other risks detailed from time to time in Incyte’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. GSK also has another advantage beyond the direct transfer of these profits to shareholders. This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the initial focus of the alliance between Agenus and Incyte, the potential benefits of the alliance and the expectation that the first clinical trials under the alliance will be initiated in 2016. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, among others, regulatory approval of the transaction, unanticipated delays and other market or economic factors, as well as the factors described under the Risk Factors section of our most recently filed Quarterly Report on Form 10-Q with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release.

These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

You may also like